Drugs Xagena
The FDA ( Food and Drug Administration ) has approved Afrezza ( Insulin human ) inhalation powder, a rapid-acting inhaled insulin to improve glycemic control in adults with diabetes mellitus.
Afrezza is a rapid-acting inhaled insulin that is administered at the beginning of each meal.
An estimated 25.8 million ( 18.8 million diagnosed and 7.0 million undiagnosed ) people in the United States, or approximately 8.3% of the population, have diabetes. Over time, high blood sugar levels can increase the risk for serious complications, including heart disease, blindness and nerve and kidney damage.
The drug’s safety and effectiveness were evaluated in a total of 3,017 participants ( 1,026 participants with type 1 diabetes and 1,991 patients with type 2 diabetes ).
The efficacy of mealtime Afrezza in adult patients with type 1 diabetes patients was compared to mealtime Insulin aspart ( fast-acting Insulin ), both in combination with basal Insulin ( long-acting Insulin ) in a 24 week study.
At week 24, treatment with basal Insulin and mealtime Afrezza provided a mean reduction in HbA1c ( hemoglobin A1c or glycosylated hemoglobin, a measure of blood sugar control ) that met the pre-specified non-inferiority margin of 0.4%.
Afrezza provided less HbA1c reduction than Insulin aspart, and the difference was statistically significant.
Afrezza was studied in adults with type 2 diabetes in combination with oral antidiabetic drugs; the efficacy of mealtime Afrezza in type 2 diabetes patients was compared to placebo inhalation in a 24 week study.
At week 24, treatment with Afrezza plus oral antidiabetic drugs provided a mean reduction in HbA1c that was statistically significantly greater compared to the HbA1c reduction observed in the placebo group.
Afrezza is not a substitute for long-acting Insulin. Afrezza must be used in combination with long-acting Insulin in patients with type 1 diabetes, and it is not recommended for the treatment of diabetic ketoacidosis, or in patients who smoke.
Afrezza has a Boxed Warning advising that acute bronchospasm has been observed in patients with asthma and chronic obstructive pulmonary disease ( COPD ). Afrezza should not be used in patients with chronic lung disease, such as asthma or COPD because of this risk.
The most common adverse reactions associated with Afrezza in clinical trials were hypoglycemia, cough, and throat pain or irritation.
The FDA approved Afrezza with a Risk Evaluation and Mitigation Strategy ( REMS ), which consists of a communication plan to inform health care professionals about the serious risk of acute bronchospasm associated with Afrezza.
The FDA is requiring the following post-marketing studies for Afrezza: a clinical trial to evaluate pharmacokinetics, safety and efficacy in pediatric patients; a clinical trial to evaluate the potential risk of pulmonary malignancy with Afrezza (t his trial will also assess cardiovascular risk and the long-term effect of Afrezza on pulmonary function ); two pharmacokinetic-pharmacodynamic euglycemic glucose-clamp clinical trials, one to characterize dose-response and one to characterize within-subject variability. ( Xagena )
Source: FDA, 2014
XagenaMedicine_2014
